Scholarlink

Background <p>The hypoxic immune microenvironment has clinical significance in predicting sensitivity to neoadjuvant chemotherapy (NAC) in patients with laryngo-hypopharyngeal cancer (LHC).</p> Methods <p>In this study, RNA sequencing was performed to screen out differentially expressed genes (DEGs). Logistic regression analysis was used to construct a predictive model. Receiver operating characteristic (ROC) curves were used to evaluate the sensitivity and specificity. Kaplan–Meier survival analysis was conducted to investigate the differences in overall survival (OS) and progression-free survival (PFS) between different risk groups. Immune infiltration analysis was performed using the “ssGSEA” method. The association between biomarkers and drug sensitivity was assessed using the CellMiner database.</p> Results <p>We screened 40 hypoxia immunity-related DEGs and constructed a five-gene prediction model with an area under the curve of 0.854. The high-risk group had a worse OS and PFS than the low-risk group in both our data and TCGA–HNSC external data set. Furthermore, immune cell infiltration played a role in the efficacy of NAC, specifically through its impact on the level of natural killer cell infiltration and migration ability. Finally, we validated gene expression in an independent clinical cohort. We also observed that patients with increased <i>AREG</i> expression showed sensitivity to the anticancer therapeutic drugs afatinib and sapitinib.</p> Conclusions <p>Our hypoxia–immune panel can accurately predict response to NAC and OS in patients with LHC and may have implications for the development of novel biomarkers and targeted therapies. <i>Trial registration:</i> This study was fully endorsed by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (protocol code: TREC2022-KY018.R1, approval date: 2022-4-21).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel hypoxia–immune biomarkers predict response to neoadjuvant chemotherapy in patients with laryngo-hypopharyngeal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Lingwa Wang,
  • Haiyang Li,
  • Ling Feng,
  • Jugao Fang,
  • Ru Wang

摘要

Background

The hypoxic immune microenvironment has clinical significance in predicting sensitivity to neoadjuvant chemotherapy (NAC) in patients with laryngo-hypopharyngeal cancer (LHC).

Methods

In this study, RNA sequencing was performed to screen out differentially expressed genes (DEGs). Logistic regression analysis was used to construct a predictive model. Receiver operating characteristic (ROC) curves were used to evaluate the sensitivity and specificity. Kaplan–Meier survival analysis was conducted to investigate the differences in overall survival (OS) and progression-free survival (PFS) between different risk groups. Immune infiltration analysis was performed using the “ssGSEA” method. The association between biomarkers and drug sensitivity was assessed using the CellMiner database.

Results

We screened 40 hypoxia immunity-related DEGs and constructed a five-gene prediction model with an area under the curve of 0.854. The high-risk group had a worse OS and PFS than the low-risk group in both our data and TCGA–HNSC external data set. Furthermore, immune cell infiltration played a role in the efficacy of NAC, specifically through its impact on the level of natural killer cell infiltration and migration ability. Finally, we validated gene expression in an independent clinical cohort. We also observed that patients with increased AREG expression showed sensitivity to the anticancer therapeutic drugs afatinib and sapitinib.

Conclusions

Our hypoxia–immune panel can accurately predict response to NAC and OS in patients with LHC and may have implications for the development of novel biomarkers and targeted therapies. Trial registration: This study was fully endorsed by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (protocol code: TREC2022-KY018.R1, approval date: 2022-4-21).